1.Effectiveness of prophylactic calcium and vitamin D supplementation for preventing post-thyroidectomy hypocalcemia: a meta-analysis
Hyeyeon MOON ; Ju Won SEOK ; Keunyoung KIM ; Hye Young KIM ; Mi Kyoung PARK ; In Joo KIM ; Kyoungjune PAK ; Sunghwan SUH
Kosin Medical Journal 2022;37(3):213-219
Background:
Postsurgical hypocalcemia is the most common and troublesome consequence of thyroidectomy. We investigated the potential role of routine calcium or vitamin D supplementation in preventing postsurgical hypocalcemia.
Methods:
We searched MEDLINE and Embase for English-language publications using the keywords “calcium,” “vitamin D,” and “thyroid cancer.” The primary outcome was any postoperative hypocalcemia, and the secondary outcome was symptomatic hypocalcemia.
Results:
Four studies that included 381 patients were eligible for this meta-analysis. A random-effects model showed no significant difference in the occurrence of hypocalcemia between calcium/vitamin D treatment and placeboo treatment. However, the occurrence of symptomatic hypocalcemia was lower in patients with calcium/vitamin D treatment. In the combined results, preoperative calcium and vitamin D supplementation were associated with a reduced incidence of symptomatic hypocalcemia.
Conclusions
Our findings support the use of preoperative calcium and vitamin D supplementation in conjunction with routine postsurgical supplementation for patients after total thyroidectomy.
2.Decreased Hippocampal Metabolism in Amnestic Mild Cognitive Impairment: Positron Emission Tomography Study
Chan hum PARK ; Young Min LEE ; JeMin PARK ; Byung Dae LEE ; EunSoo MOON ; Hee Jeong JEONG ; Soo Yeon KIM ; Kang Yoon LEE ; Hwagyu SUH ; Hye Kyung PARK ; Hak-Jin KIM ; Kyoungjune PARK ; Chi-Woong MUN ; Young-In CHUNG
Journal of Korean Geriatric Psychiatry 2020;24(1):37-41
Objective:
Little is known about factors influencing of hippocampal metabolism (HM) in mild cognitive impairment (MCI). Our objective was to determine whether HM in patients with amnestic MCI (aMCI) is decreased than non-amnestic MCI (naMCI).
Methods:
Overall, 32 MCI patients underwent 18F-fluorodeoxyglucose-positron emission tomography. They were characterized as aMCI (n=18) or naMCI (n=14) according to comprehensive neuropsychological criteria. Analysis of variances were used to assess differences on HM between aMCI and naMCI after controlling age, sex, education and Korean version of Mini Mental Status Examination.
Results:
We found that HM was more decreased in aMCI than naMCI. This result was not changed after controlling hippocampal volume.
Conclusion
Our findings suggest that aMCI is associated with decreased HM in MCI.
3.Effect of Amyloid Deposition in PET on Hippocampal Metabolism in Amnestic-Mild Cognitive Impairment : Pilot Study
Giok KIM ; Young Min LEE ; Je Min PARK ; Byung Dae LEE ; Eun Soo MOON ; Hee Jeong JEONG ; Soo Yeon KIM ; Kang Yoon LEE ; Hwagyu SUH ; Hak Jin KIM ; Kyoungjune PAK ; Chi Woong MUN ; Ji Hoon KIM ; Young In CHUNG
Journal of the Korean Society of Biological Therapies in Psychiatry 2019;25(3):251-256
OBJECTIVES: Most studies of hippocampal metabolism(HM) in amnestic mild cognitive impairment(aMCI) gave inconsistent results. Our objective was to evaluate the effect of amyloid-beta(Aβ) status on hippocampal metabolism in aMCI.METHODS: Overall, 23 aMCI underwent three-dimensional magnetic resonance imaging(MRI), ¹⁸F-fluorodeoxyglucose-positron emission tomography(¹⁸FDG-PET) and ¹⁸F-Fluorbetaben amyloid positron emission tomography (amyloid-PET). According to Aβ status on amyloid PET, 23 aMCI were classified as either Aβ+aMCI(N=13) or Aβ−aMCI(N=10). The primary outcome was HM using ¹⁸FDG-PET and we investigate the difference on HM between Aβ+aMCI and Aβ−aMCI using analysis of variance(ANOVA) model, after controlling hippocampal volume.RESULTS: We found that HM was more decreased in Aβ+aMCI than Aβ−aMCI. This result was not changed after controlling hippocampal volume.CONCLUSION: Our findings suggest that Aβ+ is associated with decreased HM, regardless of hippocampal volume, in aMCI.
Amyloid
;
Cognition Disorders
;
Metabolism
;
Pilot Projects
;
Plaque, Amyloid
;
Positron-Emission Tomography
4.Recent Survey of Effective Doses of F-18 FDG Torso PET/CT in Korea and the Current Recommendations for CT Protocols of PET/CT
Ari CHONG ; Jung Mi PARK ; Kyoungjune PAK ; Yong-il KIM ; Hyun Woo KWON ; Eun Seong LEE ; Ki Pyo NAM ; Ho-Young LEE ; Hong Jae LEE ; Ik Dong YOO ; Jae Seon EO ; Ji Young KIM ; Joon-Kee YOON ; Kyeong Min KIM ; Seong Min KIM ; Tae-Sung KIM ; ;
Nuclear Medicine and Molecular Imaging 2020;54(5):224-232
Purpose:
This study aimed to construct a database of the effective doses (ED) from F-18 fluorodeoxyglucose (FDG) torso positron emission tomography/computed tomography (PET/CT) in Korea to provide data that supports the reduction of the CT dose of PET/CT and optimization of PET/CT protocols in Korea.
Methods:
We investigated data of ED and CT parameters of FDG PET/CT. The data were analyzed by body weight groups.
Results:
A total of 31 hospitals participated in the survey (99 adults). The mean total EDs (± SD) were 8.77 ± 2.76, 10.93 ± 3.14, and 12.57 ± 3.79 mSv for the 55-, 70-, and 85-kg groups, respectively. The FDG EDs were 4.80 ± 0.98, 6.05 ± 1.15, and 6.89 ± 1.52 mSv, and the CT EDs were 4.00 ± 2.12, 4.88 ± 2.51, and 5.68 ± 2.89 mSv, respectively. Of the enrolled hospitals, 54.5% used ultra-low-dose CT protocols, and their CT ED was significantly lower than low-dose CT group in all groups (2.9 ± 1.0, 3.2 ± 1.1, and 3.3 ± 1.0 mSv vs. 6.6 ± 1.6, 7.2 ± 2.1, and 7.9 ± 2.2 mSv, all p < 0.001, respectively). In the ultra-low-dose CT group, the CT ED with the iterative reconstruction was significantly lower than that of CT without iterative reconstruction in the 55-kg group (2.4 ± 0.9 vs. 3.3 ± 0.9, p = 0.04).
Conclusions
These results and current recommendations can be helpful for optimizing PET/CT diagnostic reference level (DRL) and reducing unnecessary PET/CT radiation exposure.
5.An Autopsy Confirmed Case of Amyotrophic Lateral Sclerosis with TDP Pathology
Yu-Ri JE ; Soo-Yeon KIM ; Jung-Joon SUNG ; Myung Jun LEE ; Na-Yeon JUNG ; Jae-Hyeok LEE ; Jin-Hong SHIN ; Young Min LEE ; Jin A YOON ; Kyoungjune PARK ; Junkyeung KO ; Jae Meen LEE ; Chungsu HWANG ; Jae Woo AHN ; Suk SUNG ; Kyung-Un CHOI ; Gi Yeong HUH ; Eun-Joo KIM
Journal of the Korean Neurological Association 2022;40(2):164-167
The phosphorylated 43-kDa transactive response DNA-binding protein (TDP-43) was identified as a major disease protein in sporadic amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration. We present a case with progressive muscle weakness who was diagnosed with sporadic ALS. On postmortem examination, TDP-43 immunoreactive neuronal cytoplasmic inclusions were noted in motor cortex, hippocampus and anterior horns of spinal cord, which was compatible with ALS-TDP, stage 4. This is the first documented autopsy-confirmed ALS case with ALS-TDP pathology in Korea.